Background Current treatments with tyrosine kinase inhibitors and immune checkpoint inhibitors have limited efficacy for hepatocellular carcinoma (HCC) due to drug resistance. Emerging therapies such ...

ASCO 2025 phase 1b/2 study assessing 9MW2821, nectin-4 antibody drug conjugate, toripalimab in treatment-naïve patients, locally advanced or metastatic urothelial carcinoma.